Dr. Reddy's Laboratories Announces the Launch of Aripiprazole Tablets, USP Tablets in the U.S. Market
October 13 2016 - 6:44AM
Business Wire
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY) announced today that it has launched Aripiprazole tablets,
USP, in 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, a therapeutic
equivalent generic version of Abilify® (aripiprazole) tablets in
the United States market approved by the U.S. Food & Drug
Administration (USFDA).
The Abilify® brand and generic tablets had U.S. sales of
approximately $3.1 billion MAT for the most recent twelve months
ending in August 2016 according to IMS Health*.
Dr. Reddy’s Aripiprazole tablets 2 mg, 5 mg, 10 mg, 15 mg, 20
mg, and 30 mg are available in bottle count sizes of 30.
Abilify® is a registered trademark of Otsuka Pharmaceutical
Company.
*IMS National Sales Perspective: Retail and Non-Retail MAT
August 2016RDY-0716-127
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, Russia
& CIS and India. For more information, log on to:
www.drreddys.com.
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may,"
"will," "should," "expects," "plans," "intends," "anticipates,"
"believes," "estimates," "predicts," "potential," or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates , interest rates , persistency
levels and frequency / severity of insured loss events (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.
The company assumes no obligation to update any information
contained herein.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161013005637/en/
Dr. Reddy’s Laboratories Ltd.INVESTOR RELATIONSSaunak
Savla, +91-40-49002135saunaks@drreddys.comorMEDIA
RELATIONSCalvin Printer,
+91-40-49002121calvinprinter@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Sep 2023 to Sep 2024